Electrophysiology

Which Pacing Method is Best for Low-Risk Patients?

Right ventricular pacing (RVP) is the default for patients with AV block and normal LV function, because it’s simple, reliable, and guideline-backed. But a new randomized trial in JAMA suggests left bundle branch area pacing (LBBAP) is the better call, even in this lower-risk group.

  • RVP remains widely used in AV block patients, but since it uses the heart muscle cells to deliver pacing, it’s linked to higher risks of HF, AFib, and mortality.
  • Studies like BLOCK-HF suggest biventricular pacing is better than RVP when LVEF is reduced, but that benefit hasn’t been shown with preserved LVEF.
  • Furthermore, LBBAP trials (like LBBP-FAVOR, PACE-HF, CSPACE) were small and enrolled higher-risk patients, so current guidelines still favor RVP when LV function is normal.

Enter LEAP-Block to settle the score using a superiority trial design that randomized 499 AVB patients across China to LBBAP or RVP, with a primary composite endpoint of all-cause death, HF events, or upgrade to biventricular pacing 24 months post implant.

  • Notably, patients started with an average LVEF of 64% (quite normal), and 54.6% had complete AV block.
  • All patients received a dual-chamber pacemaker for direct comparison between the pacing methods.

After 24 months, the headline result was hard to miss. Patients who received LBBAP were much less likely to experience the composite end point of death, HF, or upgrade.

  • Specifically, these events occurred in 2.4% of LBBAP patients vs. 12.5% of RVP patients.
  • That benefit held across all of the study’s prespecified subgroups like sex, baseline QRS duration, and underlying cardiac disease.
  • Procedural success was also very similar (97.9% vs. 99.6%), though LBBAP lead placement took a bit longer (12 vs. 7 minutes).

Looking under the data’s hood tells us where the real advantage is and nearly all of the benefit comes from fewer HF events (LBBAP: 3.4% vs. RVP: 11.3%).

  • Thus, there were no statistically significant differences in the other separate outcomes like death, BiV upgrades, device complications, or pacing-induced cardiomyopathy.

The Takeaway


LBBAP’s success has already outpaced (pun intended) the smaller study evidence backing it, and LEAP-Block now gives even stronger randomized support for its use in lower-risk AV block patients. Add in the confirmed HF payoff and the “RVP by default” guidelines seem due for a change.

Get twice-weekly insights on the biggest stories shaping cardiology.

You might also like

Like the website? You'll love the newsletter

Completely free. Every Monday and Thursday.

CW Phone Square